Theriva Biologics Inc. (TOVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE MKT
Market Cap: $6.42M
Last updated: Nov 17, 2026 at 4:10 PM ET
Theriva Biologics Inc. (TOVX) Statistics
Theriva Biologics (TOVX) has a market cap of $6.42M and an enterprise value of $839.00K. It kept -2909.33% of revenue as net income over the last 12 months. Its share count is up 374.27% from a year earlier.
Total Valuation
Enterprise value is 86.94% below the market cap, as cash exceeds debt.
| Market Cap | $6.42M |
|---|---|
| Enterprise Value | $839.00K |
| Latest price (Nov 17, 2026) | $0.14 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 21.7x and 0.6x.
| P/S Ratio | 21.7x |
|---|---|
| Forward P/S | 21.4x |
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 47.81% over 52 weeks and trades 30.00% below its 50-day average.
| Beta (1Y) | 2.49 |
|---|---|
| 52-Week Change | -47.81% |
| 1-Month Change | -30.83% |
| 3-Month Change | -37.18% |
| 6-Month Change | -46.95% |
| 5-Year Change | -99.84% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -47.81% |
| Total Return (3Y CAGR) | -76.00% |
| Total Return (5Y CAGR) | -72.58% |
| Max Drawdown (1Y) | -65.85% |
| Max Drawdown (3Y) | -99.09% |
| Sharpe Ratio (1Y) | -0.55 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $0.20 |
| 200-Day Average | $0.24 |
| 52-Week Range | $0.14 to $0.49 |
| RSI (14 Days) | 27.9 |
| Average Volume (20 Days) | 5.31M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.21x current liabilities, and total debt is 0.27x shareholder equity.
| Current Ratio | 1.21x |
|---|---|
| Quick Ratio | 1.21x |
| Debt / Equity | 0.27x |
Returns and Efficiency
Return on invested capital is -52.27% over the last 12 months, against a 5-year average of -64.75%.
| Return on Equity (ROE) | -81.17% |
|---|---|
| Return on Assets (ROA) | -27.66% |
| Return on Invested Capital (ROIC) | -52.27% |
| ROE (5Y Average) | -79.66% |
| ROA (5Y Average) | -43.11% |
| ROIC (5Y Average) | -64.75% |
| Asset Turnover | 0.01x |
Scores
TOVX has an Altman Z-Score of -16.89, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -16.89 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $300.00K over the last 12 months is up 94.81% from the 12 months before.
| Revenue | $300.00K |
|---|---|
| Revenue Growth (YoY) | +94.81% |
| Gross Profit | $273.00K |
| Operating Income | -$9.02M |
| Pretax Income | -$8.73M |
| Net Income | -$8.73M |
| Reported EPS (TTM) | -$0.25 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 34.06% of the $31.56M in total assets.
| Cash and Equivalents | $8.47M |
|---|---|
| Total Debt | $2.89M |
| Net Cash | $5.59M |
| Net Cash Per Share | $0.12 |
| Working Capital | $1.84M |
| Shareholder Equity | $10.75M |
| Book Value Per Share | $0.23 |
| Tangible Book Value | -$8.20M |
| Total Assets | $31.56M |
| Total Liabilities | $20.81M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$11.28M |
|---|---|
| FCF Per Share | -$0.25 |
| Depreciation and Amortization | $97.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -3006.33%.
| Gross Margin | 91.00% |
|---|---|
| Operating Margin | -3006.33% |
| Pretax Margin | -2909.33% |
| Net Margin | -2909.33% |
Dividends and Yields
TOVX does not pay a dividend.
| Buyback Yield | -136.30% |
|---|---|
| Shareholder Yield | -136.30% |
Stock Splits
The last split was a 1-for-25 reverse split on Aug 26, 2024.
| Last Split Date | Aug 26, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TOVX
What is TOVX's market cap?
Theriva Biologics has a market cap of $6.42M. Its enterprise value, which adds debt and subtracts cash, is $839.00K.
How many shares of TOVX are outstanding?
Theriva Biologics has 45.89M shares outstanding. The count is up 374.27% from a year earlier.
Does TOVX pay a dividend?
No. Theriva Biologics does not pay a dividend.
How much debt does TOVX have?
Theriva Biologics has $2.89M of total debt and $8.47M of cash and equivalents, a net cash position of $5.59M.
TOVX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors